Answers are grounded in this paper and cite their sources.
Recombinant adeno-associated virus (rAAV) vectors have moved central nervous system (CNS) gene therapy from experimental proof of concept to clinically validated treatment, yet therapeutic design remains highly dependent on disease mechanism, cellular distribution, and treatment timing. This narrative review examines recent progress in rAAV-based interventions for neurodevelopmental disorders (NDDs) and neurodegenerative disorders. For monogenic NDDs, gene replacement is most applicable to loss-of-function conditions with compatible payload size and tolerable expression, whereas dominant-negative, gain-of-function, and dosage-sensitive disorders may require allele-selective silencing or precise DNA or RNA editing. Rett syndrome illustrates both the reversibility of postnatal dysfunction and the need for tightly regulated transgene expression. Spinal muscular atrophy provides the leading translational paradigm: rAAV9-mediated SMN1 replacement demonstrates the value of early diagnosis, adequate tissue exposure, and treatment before irreversible neuronal loss. For complex neurodegenerative diseases, emerging strategies extend beyond simple gene addition. APOE-directed editing and protective-variant replacement may enable genotype-informed intervention in Alzheimer's disease, whereas Parkinson's disease programs combine restoration of dopamine synthesis, neuroprotection, and genetically encoded circuit modulation. Across these indications, major barriers include incomplete and nonselective CNS delivery, immune and dose-related toxicity, limited redosing, durable control of transgene or editor activity, off-target effects, and uncertain translation from animal models to humans. Progress over the next decade will depend on human-compatible vectors, cell-selective and regulatable expression, rigorous long-term safety assessment, biomarker-guided trials, and rational combinations that connect molecular target engagement to meaningful neurological benefit.
No takes yet. Share an insight, caveat, or question.
Zilong Qiu (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: